Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SpringWorks Therapeutics, Inc. - common stock (NQ: SWTX )

49.77 -1.11 (-2.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,648,598
Open 50.65
Bid (Size) 49.15 (2)
Ask (Size) 50.19 (6)
Prev. Close 50.88
Today's Range 48.64 - 51.51
52wk Range 28.21 - 62.00
Shares Outstanding 49,127,913
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?
Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock. 
Via Stocktwits
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Performance

YTD
+37.94%
+37.94%
1 Month
-7.83%
-7.83%
3 Month
+25.21%
+25.21%
6 Month
+28.74%
+28.74%
1 Year
+0.04%
+0.04%

More News

Read More
Assessing SpringWorks Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
Top 3 Health Care Stocks You May Want To Dump In February
Via Benzinga
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 20, 2025
Via Benzinga
Smart Money Is Betting Big In SWTX Options
Via Benzinga
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect
Via Stocktwits
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
SpringWorks Therapeutics Secures FDA Approval For Second Cancer Drug
Via Benzinga
Exposures Product Safety
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Crude Oil Rises Sharply; Manhattan Associates Shares Slide
Via Benzinga
Exposures Fossil Fuels
Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets
Via Stocktwits
Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss
Via Benzinga
Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday
Via Benzinga
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
Via Investor's Business Daily
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Plug Power, Capri And Frontline Are Among Top Mid Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
Via Benzinga
SpringWorks Therapeutics Stock Gets A RS Rating Lift
Via Investor's Business Daily
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.